A recent phase II neoadjuvant study (neoMONARCH) that was based on the administration of abemaciclib and anstrazole to postmenopausal women with stage I-III HR-positive, HER2-negative breast cancer showed that the combined administration of the two drugs when compared to anastrozole alone achieved complete cell cycle arrest and enhanced immune activation (enhanced antigen presentation and activated T-cell phenotypes) [366]. Here, ERBB2 is linked to breast carcinoma.